News
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
“We are thrilled to announce the initiation of our global Phase 3 DEEp Program with our first ... For such statements, Longboard claims the protection of the Private Securities Litigation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback